Company intelligence / Profile preview
Tripod Therapeutics
Boston, Massachusetts, United Statestripodtx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tripod Therapeutics is a pre-clinical stage biotechnology company focused on developing a new class of cancer therapeutics that target the DNA replication machinery. The company's proprietary platform identifies small molecule inhibitors that simultaneously target three essential DNA polymerases (alpha, delta, and epsilon), a strategy designed to overcome the resistance mechanisms often seen with single-target inhibitors. By disrupting the core replication complex, Tripod aims to induce catastrophic DNA damage specifically in cancer cells while sparing healthy tissue. Their lead programs are currently being evaluated for the treatment of various hard-to-treat solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tripod Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tripod Therapeutics.